Two Tales: One Story
Subodh Verma, Darren K. McGuire, Mikhail Kosiborod
Abstract
lthough the sodium-glucose cotransporter-2 (SGLT2) inhibitors were originally developed to manage hyperglycemia in people with type 2 diabetes, they have consistently been found to improve heart failure and kidney outcomes. In contrast to the initial SGLT2 inhibitor outcome trials that demonstrated robust reductions for incident heart failure in people with type 2 diabetes, 2 recent trials-EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction; with empagliflozin) 1 and DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; with dapagliflozin) 2,3 -have examined the efficacy of SGLT2 inhibitors to treat patients with heart failure with reduced ejection fraction (HFrEF), with or without type 2 diabetes. We compare the 2 trials and their results.